ZURICH, Jan 8 (Reuters) - Roche on Wednesday

said it planned to complete its purchase of U.S.

biopharmaceutical company Poseida Therapeutics via its

subsidiary Blue Giant Acquisition Corp.

Roche said it has accepted for payment nearly 65 million

shares in Poseida - equivalent to 66% of the California

company's stock - which had been tendered by shareholders at a

price of $9 per share, with additional contingent payment of up

to $4 per share.